GSK · NYSE
GSK plc
$50.50 -0.70 (-1.38%)
Company overview
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has collaboration agreements with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc. for oligonucleotide platform development.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Market cap
- $101B
- Employees
- 68,629
- Headquarters
- Brentford
- Website
- gsk.com
- CEO
- Luke Victor Miels
- Listed
- March 28, 1980
- P/E
- 14.77
- Dividend yield
- 3.67%
Company financials
- Revenue
- $32.8B
- Gross profit
- $23.8B
- Operating income
- $8.4B
- EBITDA
- $11.3B
- Net income
- $5.8B
- EPS
- $3.42
- Total assets
- $82.9B
- Total debt
- $25.1B
- Gross margin
- 72.68%
- Net margin
- 17.78%
- Earnings yield
- 6.77%
No annual product segmentation.
Showing FY 2025
GSK
1D
NYSE
O50.29H51.44L49.97C51.21+1.19 (+2.38%)Vol4.28M